This drug was initially approved by the China Food and Drug Administration in 2014 for the treatment of relapsed or refractory peripheral T cell lymphoma (PTCL); in 2024, it was approved for the treatment of previously untreated double-expressor (MYC+/BCL2+) DLBCL.24 This evidence concerns the gene MYC and diffuse large B-cell lymphoma.